Remove 2026 Remove Patients Remove Side effects
article thumbnail

Jazz Pharma uses flying pig for huge grey area DTC

World of DTC Marketing

billion by 2026. Jazz Pharmaceuticals has introduced a new prescription medication for patients with sleep apnea/narcolepsy that “helped adults get up to 9 hours of improved wakefulness in clinical studies at 12 weeks” and they’re using a flying pig on their DTC. This DTC is an embaressment.

Pharma 181
article thumbnail

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain. The drug is also undergoing trials both for adjunctive therapy to existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer’s disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi looks east with €300m Innovent cancer alliance

pharmaphorum

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world’s second-largest pharma market. It is being tested in a wide range of solid tumours and lymphoma, alone and in combination with other drugs.

article thumbnail

FDA makes moves to advance ALS research ahead of upcoming Amylyx AdCom

Pharmaceutical Technology

This was following a dogged advocacy campaign from ALS clinicians and patients, and the release of additional AMX0035 data. Dr Merit Cudkowicz, a co-principal investigator in Amylyx’s clinical trials, says patients and investigators are pushing for an approval given the unmet need for therapies. “By The FDA’s action plan.

FDA 98
article thumbnail

NewAmsterdam goes public to advance drug in abandoned class

pharmaphorum

That will fund operations until 2026, beyond the readout of phase 3 trials including the BROADWAY study of obicetrapib in adults with heterozygous familial hypercholesterolaemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD) who can’t control LDL cholesterol on statin drugs alone.